EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Idorsia partners with Antares to develop a self-administered drug-device product for selatogrel, a P2Y12 receptor antagonist in development in acute myocardial infarction. Release 

> Azeria Therapeutics raised £32 million ($41 million) to advance an estrogen receptor positive breast cancer drug. Syncona provided most of the money. Statement 

> The FDA granted orphan drug designation to ProQR Therapeutics’ QR-1123 in autosomal dominant retinitis pigmentosa. Release 

> Galapagos confirmed the interim futility analysis for its idiopathic pulmonary fibrosis phase 3 is likely to take place early in 2021. The target is later than analysts at Jefferies hoped. Webcast

> Zealand Pharma delayed the readout from its phase 3 glepaglutide program to the first half of 2021. The target slipped from late 2020 due to delays in the activation of U.K. and U.S. trial sites. Statement